Putting Patients First Blog
APRIL 14, 2025
While we recognize CMS intent to strengthen program integrity and reduce fraud, we are deeply concerned that several provisions in this rule will create obstacles to coverage, increase out-of-pocket costs, and disproportionately impact vulnerable populations.
Integra X Files
MAY 22, 2023
Prior authorization has been popular with the insurance industry because it works. This is known as the sentinel effect, and in the initial stages, providers accommodated the process without much complaint. The health insurance industry didn’t have many other tools to suppress demand, so it went with the sentinel effect by default.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 27, 2022
Jennifer Mathieu, director of government relations at the Academy of Managed Care Pharmacy (AMCP), tells us why the organisation backed the pre-approval information exchange (PIE) Act of 2022 and how the legislation will empower companies to share information with healthcare payers and plans during the FDA approval process. .
Putting Patients First Blog
SEPTEMBER 3, 2024
The NHC appreciates CMS’ efforts to gather patient-centered data as part of this ICR and its commitment to making the process more relevant for patients and patient organizations. While we acknowledge these improvements, it is important to note that some aspects of the data collection process may remain challenging.
Putting Patients First Blog
JANUARY 10, 2024
Making available more specific information about total costs and coverage will ensure that all consumers have comprehensive information to help them make smart health care decisions. These resources should aim to clarify insurance terms and concepts, aiding consumers in navigating the complexities of selecting a health plan.
pharmaphorum
JANUARY 28, 2021
Pharmacists have more insight into a patient’s insurance coverage than most providers, so this change could create a lot of value for patients throughout the country. It will be the first time pharmacists can help patients access a more cost-effective biosimilar since the launch of the category five years ago. About the author.
Pharmaceutical Technology
NOVEMBER 30, 2022
A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% In the US, most private health insurers have been slow to cover the cost of anti-obesity therapeutics. Furthermore, an increase in a sedentary lifestyle, partly brought on by the Covid-19 pandemic, saw a further rise in the obese population.
Expert insights. Personalized for you.
52 
Let's personalize your content